78. 下垂体前葉機能低下症 Hypopituitarism Clinical trials / Disease details
臨床試験数 : 492 / 薬物数 : 341 - (DrugBank : 47) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 100
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2005-005587-82-GR (EUCTR) | 28/11/2007 | 28/06/2007 | A Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of PHA-794428 in Adult Growth Hormone Deficient patients - N/A | A Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of PHA-794428 in Adult Growth Hormone Deficient patients - N/A | Adult Growth Hormone Deficiency MedDRA version: 9.1;Level: LLT;Classification code 10056438;Term: Growth hormone deficiency | Product Name: N/A Product Code: PHA-794,428 INN or Proposed INN: N/A Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH Product Name: N/A Product Code: PHA-794,428 INN or Proposed INN: N/A Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH | Pfizer Ltd | NULL | Not Recruiting | Female: yes Male: yes | 170 | Czech Republic;United Kingdom;Netherlands;Denmark;Italy;Greece;Poland;Sweden | |||
| 2 | EUCTR2005-005587-82-PL (EUCTR) | 07/07/2007 | 31/05/2007 | A Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of Pha-794428 in Adult Growth Hormone Deficient patients - N/A | A Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of Pha-794428 in Adult Growth Hormone Deficient patients - N/A | Adult Growth Hormone Deficiency MedDRA version: 9.1;Level: LLT;Classification code 10056438;Term: Growth hormone deficiency | Product Name: N/A Product Code: PHA-794,428 INN or Proposed INN: N/A Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH Product Name: N/A Product Code: PHA-794,428 INN or Proposed INN: N/A Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH | Pfizer Ltd | NULL | Not Recruiting | Female: yes Male: yes | 170 | Phase 2 | Czech Republic;Greece;Belgium;Poland;Denmark;Netherlands;Germany;Italy;United Kingdom;Sweden | ||
| 3 | EUCTR2005-005587-82-CZ (EUCTR) | 15/02/2007 | 25/10/2006 | A Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of Pha-794428 in Adult Growth Hormone Deficient patients - N/A | A Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of Pha-794428 in Adult Growth Hormone Deficient patients - N/A | Adult Growth Hormone Deficiency MedDRA version: 9.1;Level: LLT;Classification code 10056438;Term: Growth hormone deficiency | Product Name: N/A Product Code: PHA-794,428 INN or Proposed INN: N/A Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH Product Name: N/A Product Code: PHA-794,428 INN or Proposed INN: N/A Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH | Pfizer Limited | NULL | Not Recruiting | Female: yes Male: yes | 170 | United Kingdom;Czech Republic;Netherlands;Denmark;Italy;Greece;Poland;Sweden | |||
| 4 | EUCTR2005-005587-82-NL (EUCTR) | 08/08/2006 | 12/05/2006 | A Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of Pha-794428 in adult growth hormone deficient Patients - N/A | A Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of Pha-794428 in adult growth hormone deficient Patients - N/A | Adult Growth Hormone Deficiency MedDRA version: 8.1;Level: LLT;Classification code 10056438 | Product Name: N/A Product Code: PHA-794,428 INN or Proposed INN: N/A Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH Product Name: N/A Product Code: PHA-794,428 INN or Proposed INN: N/A Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH | Pfizer | Pfizer | Not Recruiting | Female: yes Male: yes | 136 | Czech Republic;United Kingdom;Netherlands;Denmark;Italy;Greece;Poland;Sweden | |||
| 5 | EUCTR2005-005587-82-IT (EUCTR) | 02/08/2006 | 23/06/2006 | A DOUBLE BLIND PARALLEL GROUP RANDOMISED MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACODYNAMIC RESPONSE AND SAFETY OF PHA-794428 IN ADULT GROWTH HORMONE DEFICIENT PATIENTS - ND | A DOUBLE BLIND PARALLEL GROUP RANDOMISED MULTIPLE DOSE STUDY TO EVALUATE THE PHARMACODYNAMIC RESPONSE AND SAFETY OF PHA-794428 IN ADULT GROWTH HORMONE DEFICIENT PATIENTS - ND | Adult growth hormone deficiency AGHD . MedDRA version: 6.1;Level: PT;Classification code 10056438 | Product Code: PHA-794,428 Product Code: PHA-794,428 | PFIZER | NULL | Not Recruiting | Female: yes Male: yes | 136 | Czech Republic;United Kingdom;Netherlands;Denmark;Italy;Greece;Poland;Sweden | |||
| 6 | EUCTR2005-005593-79-BE (EUCTR) | 31/07/2006 | 11/05/2006 | A Double blind, third party open, single dose study to explore the safety, pharmacokinetics and pharmacodynamics of pha-794428 in paediatric patients with growth hormone deficiency - N/A | A Double blind, third party open, single dose study to explore the safety, pharmacokinetics and pharmacodynamics of pha-794428 in paediatric patients with growth hormone deficiency - N/A | Paediatric Growth Hormone Deficiency MedDRA version: 8.1;Level: LLT;Classification code 10056438 | Product Name: N/A Product Code: PHA-794428 INN or Proposed INN: N/A Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH Product Name: N/A Product Code: PHA-794428 INN or Proposed INN: N/A Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH | Pfizer N.V./S.A. | NULL | Not Recruiting | Female: yes Male: yes | 32 | Spain;Belgium;Germany;United Kingdom | |||
| 7 | EUCTR2005-005587-82-BE (EUCTR) | 03/07/2006 | 22/03/2006 | A Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of Pha-794428 in Adult Growth Hormone Deficient patients - N/A | A Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of Pha-794428 in Adult Growth Hormone Deficient patients - N/A | Adult Growth Hormone Deficiency MedDRA version: 9.1;Level: LLT;Classification code 10056438;Term: Growth hormone deficiency | Product Name: N/A Product Code: PHA-794,428 INN or Proposed INN: N/A Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH Product Name: N/A Product Code: PHA-794,428 INN or Proposed INN: N/A Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH | Pfizer NV/SA | NULL | Not Recruiting | Female: yes Male: yes | 170 | Czech Republic;Greece;Poland;Belgium;Denmark;Netherlands;Germany;Italy;United Kingdom;Sweden | |||
| 8 | NCT00308464 (ClinicalTrials.gov) | July 2006 | 27/3/2006 | A Study To Evaluate The Dose Response And Safety Of PHA-794428 In Adults With Growth Hormone Deficiency | A Double Blind Parallel Group Randomised Multiple Dose Study To Evaluate The Pharmacodynamic Response And Safety Of PHA-794428 In Adult Growth Hormone Deficient Patients | Growth Hormone Deficiency | Drug: PHA-794428 | Pfizer | NULL | Terminated | 18 Years | 65 Years | Both | 136 | Phase 2 | Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Poland;Slovakia;Spain;Sweden;United Kingdom |
| 9 | EUCTR2005-005587-82-DE (EUCTR) | 21/06/2006 | 06/03/2006 | A Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of Pha-794428 in adult growth hormone deficient Patients - N/A | A Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of Pha-794428 in adult growth hormone deficient Patients - N/A | Adult Growth Hormone Deficiency MedDRA version: 8.1;Level: LLT;Classification code 10056438;Term: Growth hormone deficiency | Product Name: N/A Product Code: PHA-794,428 INN or Proposed INN: N/A Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH Product Name: N/A Product Code: PHA-794,428 INN or Proposed INN: N/A Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH | Pfizer Pharma GmbH | NULL | Not Recruiting | Female: yes Male: yes | 136 | Czech Republic;Greece;Poland;Denmark;Netherlands;Germany;Italy;United Kingdom;Sweden | |||
| 10 | EUCTR2005-005587-82-SE (EUCTR) | 12/06/2006 | 02/03/2006 | A Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of Pha-794428 in Adult Growth Hormone Deficient patients - N/A | A Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of Pha-794428 in Adult Growth Hormone Deficient patients - N/A | Adult Growth Hormone Deficiency MedDRA version: 9.1;Level: LLT;Classification code 10056438;Term: Growth hormone deficiency | Product Name: N/A Product Code: PHA-794,428 INN or Proposed INN: N/A Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH Product Name: N/A Product Code: PHA-794,428 INN or Proposed INN: N/A Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH | Pfizer AB;Pfizer Ltd | Not Recruiting | Female: yes Male: yes | 170 | Czech Republic;United Kingdom;Netherlands;Denmark;Italy;Greece;Poland;Sweden | ||||
| 11 | EUCTR2005-005593-79-DE (EUCTR) | 09/06/2006 | 03/04/2006 | A Double blind, single dose study to explore the safety, pharmacokinetics and pharmacodynamics of pha-794428 in paediatric patients with growth hormone deficiency - N/A | A Double blind, single dose study to explore the safety, pharmacokinetics and pharmacodynamics of pha-794428 in paediatric patients with growth hormone deficiency - N/A | Paediatric Growth Hormone Deficiency MedDRA version: 8.1;Level: LLT;Classification code 10056438 | Product Name: N/A Product Code: PHA-794428 INN or Proposed INN: N/A Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH Product Name: N/A Product Code: PHA-794428 INN or Proposed INN: N/A Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH | Pfizer Pharma GmbH | NULL | Not Recruiting | Female: yes Male: yes | 32 | United Kingdom;Germany;Spain | |||
| 12 | EUCTR2005-005593-79-GB (EUCTR) | 02/06/2006 | 21/03/2006 | A Double blind, third party open, single dose study to explore the safety, pharmacokinetics and pharmacodynamics of pha-794428 in paediatric patients with growth hormone deficiency - N/A | A Double blind, third party open, single dose study to explore the safety, pharmacokinetics and pharmacodynamics of pha-794428 in paediatric patients with growth hormone deficiency - N/A | Paediatric Growth Hormone Deficiency MedDRA version: 8.1;Level: LLT;Classification code 10056438 | Product Name: N/A Product Code: PHA-794428 INN or Proposed INN: N/A Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH Product Name: N/A Product Code: PHA-794428 INN or Proposed INN: N/A Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH | Pfizer Limited | NULL | Not Recruiting | Female: yes Male: yes | 32 | Germany;United Kingdom;Spain | |||
| 13 | EUCTR2005-005593-79-ES (EUCTR) | 31/05/2006 | 04/04/2006 | A Double blind, third party open, single dose study to explore the safety, pharmacokinetics and pharmacodynamics of pha-794428 in paediatric patients with growth hormone deficiency | A Double blind, third party open, single dose study to explore the safety, pharmacokinetics and pharmacodynamics of pha-794428 in paediatric patients with growth hormone deficiency | Paediatric Growth Hormone Deficiency MedDRA version: 8.1;Level: LLT;Classification code 10056438 | Product Code: PHA-794428 Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH Product Code: PHA-794428 Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH | Pfizer SA | NULL | Not Recruiting | Female: yes Male: yes | 32 | Phase 2 | Belgium;Spain;Germany;United Kingdom | ||
| 14 | EUCTR2005-005587-82-GB (EUCTR) | 17/05/2006 | 20/04/2006 | A Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of Pha-794428 in adult growth hormone deficient Patients - N/A | A Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of Pha-794428 in adult growth hormone deficient Patients - N/A | Adult Growth Hormone Deficiency MedDRA version: 8.1;Level: LLT;Classification code 10056438 | Product Code: PHA-794,428 Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH Product Code: PHA-794,428 Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH | Pfizer Limited | NULL | Not Recruiting | Female: yes Male: yes | 136 | Czech Republic;United Kingdom;Netherlands;Denmark;Italy;Greece;Poland;Sweden | |||
| 15 | EUCTR2005-005587-82-DK (EUCTR) | 26/04/2006 | 15/03/2006 | A Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of Pha-794428 in adult growth hormone deficient Patients - N/A | A Double Blind Parallel Group Randomised Multiple Dose Study to Evaluate the pharmacodynamic response and safety of Pha-794428 in adult growth hormone deficient Patients - N/A | Adult Growth Hormone Deficiency MedDRA version: 8.1;Level: LLT;Classification code 10056438 | Product Name: N/A Product Code: PHA-794,428 INN or Proposed INN: N/A Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH Product Name: N/A Product Code: PHA-794,428 INN or Proposed INN: N/A Other descriptive name: Pegylated polypeptide hormone of human recombinant origin PEG-hGH | Pfizer Limited | NULL | Not Recruiting | Female: yes Male: yes | 136 | Czech Republic;United Kingdom;Netherlands;Denmark;Italy;Greece;Poland;Sweden | |||
| 16 | NCT00314938 (ClinicalTrials.gov) | April 2006 | 13/4/2006 | A Single Dose Study to Evaluate the PK-PD Response and Safety of PHA-794428 in Children With Growth Hormone Deficiency | A Double Blind, Single Dose Study To Explore The Safety, Pharmacokinetics And Pharmacodynamics Of PHA-794428 In Pediatric Patients With Growth Hormone Deficiency | Growth Hormone Deficiency | Drug: PHA-794428 | Pfizer | NULL | Terminated | 6 Years | 12 Years | Both | 32 | Phase 2 | Belgium;France;Germany;Israel;United Kingdom;Spain |
| 17 | EUCTR2005-001658-25-BE (EUCTR) | 16/06/2005 | 05/07/2005 | An open label, two period crossover study to explore the safety, pharmacokinetics and pharmacodynamics of PHA-794428 after single subcutaneous injections in adult male patients with growth hormone deficiency. | An open label, two period crossover study to explore the safety, pharmacokinetics and pharmacodynamics of PHA-794428 after single subcutaneous injections in adult male patients with growth hormone deficiency. | AGHD Adult Growth Hormone Deficiency | Product Code: PHA-794428 Product Code: PHA-794428 | Pfizer Global Research and Development | NULL | Not Recruiting | Female: no Male: yes | 8 | Belgium |